Mulder Verena C, Bastiaans Jeroen, van Leuven Cornelis J M, van Meurs Jan C, Kluft Cornelis
Rotterdam Ophthalmic Institute, Rotterdam Eye Hospital, Rotterdam, the Netherlands.
Department of Immunology, Erasmus Medical Centre, Rotterdam, the Netherlands.
Ophthalmologica. 2018;240(1):23-28. doi: 10.1159/000487757. Epub 2018 Apr 4.
To measure prothrombin fragments (F1+2) and thrombin-antithrombin complex (TAT) in vitreous and subretinal fluid (SRF) of rhegmatogenous retinal detachment (RRD) patients and to validate and further specify our earlier finding of increased thrombin activity in patients with proliferative vitreoretinopathy (PVR).
F1+2 and TAT were measured in 31 vitreous and 16 SRF samples using the Enzygnost® immunoassays.
We found significant levels of F1+2 and TAT in the vitreous of all patients with RRD compared to patients with macular hole or macular pucker. However, there was no significant difference between patients who would develop PVR in the future, had established PVR, and patients with uncomplicated RRD both in vitreous concentrations of F1+2 (Kruskal-Wallis p = 0.963) and TAT (p = 0.516).
The analysis of F1+2 and TAT confirmed significant thrombin generation in both vitreous and SRF of patients with RRD. An imbalance between the thrombin regulation mechanisms TAT and α2-macroglobulin possibly explains the difference from our previous findings.
检测孔源性视网膜脱离（RRD）患者玻璃体液和视网膜下液（SRF）中的凝血酶原片段（F1+2）和凝血酶-抗凝血酶复合物（TAT），并验证和进一步明确我们之前关于增生性玻璃体视网膜病变（PVR）患者凝血酶活性增加的发现。
使用Enzygnost®免疫分析法检测31份玻璃体液样本和16份视网膜下液样本中的F1+2和TAT。
与黄斑裂孔或黄斑皱襞患者相比，我们发现所有RRD患者玻璃体液中F1+2和TAT水平均显著升高。然而，未来会发生PVR的患者、已确诊PVR的患者以及无并发症RRD患者的玻璃体液中F1+2浓度（Kruskal-Wallis检验p = 0.963）和TAT浓度（p = 0.516）之间均无显著差异。
F1+2和TAT分析证实RRD患者的玻璃体液和视网膜下液中均有显著的凝血酶生成。凝血酶调节机制TAT和α2-巨球蛋白之间的失衡可能解释了与我们之前研究结果的差异之处。
